From heart disease to neurodegeneration, Novartis makes bold deals in 2025 to expand its drug pipeline globally.

With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.

As Labiotech attented the NLS Days this week, it was the occasion to learn more about the biotech industry in Sweden.

Discover the emerging field of AI-based peptide discovery and design – could this signal the beginning of a golden age for ...

Discover five promising Prader-Willi syndrome therapies climbing the clinical ladder and nearing FDA approval in the coming ...

Home to a well-established hub with strong investment and startup activity, discover what makes Cambridge's biotech scene so ...

BIOSPAIN showed how partnering conferences connect public funding, venture capital, and pharma to drive biotech innovation to ...

The Asabys-Aliath integration signals how European biotech VCs are scaling and adapting amid funding pressures.

Discover how AKIGAI’s EGFR inhibitors may redefine neuropathic pain therapy and offer hope for complex regional pain syndrome (CRPS).